Knobil, E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;30:1–36.Google Scholar

Stanger, YD, Yovich, JL Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. B J Obstet Gynecol. 1985;92:385–93.Google ScholarPubMed

Frattarelli, JL, Hillensjö, T, Broekmans, FJ et al. Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation. Reprod Biol Endocrinol. 2013;11:90.CrossRefGoogle ScholarPubMed

Hughes, EG, Fedorkow, DM, Daya, S et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 1992;58:888–96.Google Scholar

Schally, AV, Nair, RMG, Redding, TW et al. Isolation of the luteinizing hormone and follicle stimulating hormone-releasing hormone from porcine hypothalami. J Biol Chem. 1971;246:7230–6.Google Scholar

Feldberg, D, Ashkenazi, J, Dicker, D et al. Ovarian cysts formation: a complication of gonadotropin-releasing hormone agonist therapy. Fertil Steril. 1989;51:42–5.CrossRefGoogle ScholarPubMed

Biljan, MM, Lapensée, L, Mahutte, N et al. Effects of ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment. Fertil Steril. 2000;74:941–5.Google Scholar

Reissmann, T, Felberbaum, R, Diedrich, K et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995;10:1974–81.CrossRefGoogle Scholar

Duijkers, IJM, Klipping, C, Willemsen, WNP et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod. 1998;13:2392–8.Google Scholar

Oberye, JJ, Mannaerts, BM, Kleijn, HJ, Timmer, CJ Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999;72:1001–5.Google Scholar

Oberye, JJ, Mannaerts, BM, Huisman, JA, Timmer, CJ Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 1999;72:1006–12.Google Scholar

Griesinger, G, Diedrich, K, Devroey, P, Kolibianakis, EM GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159–68.CrossRefGoogle ScholarPubMed

Sommer, L, Zanger, K, Dyong, T et al. Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women. Eur J Endocrinol. 1994;131:280–5.Google Scholar

Duijkers, IJM, Klipping, C, Willemsen, WNP et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod. 1998;13:2392–8.Google Scholar

Erb, K, Klipping, C, Duijkers, I et al. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril. 2001;75:316–23.Google Scholar

Griesinger, G, Felberbaum, RE, Schultze-Mosgau, A, Diedrich, K. Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents? Drugs. 2004;64(6):563–75.Google Scholar

Nagaraja, NV, Pechstein, B, Erb, K et al. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Clin Pharmacol Ther. 2000;68: 617–25.CrossRefGoogle ScholarPubMed

Frattarelli, JL, Hillensjö, T, Broekmans, FJ et al. Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation. Reprod Biol Endocrinol. 2013 September 12;11:90.Google Scholar

Griesinger, G, Dawson, A, Schultze-Mosgau, A, Finas, D, Diedrich K and Felberbaum R. Assessment of luteinizing hormone levels in the gonadotropin-releasing hormone-antagonist protocol. Fertility Sterility 2006 March;85(3):791–3.Google Scholar

Griesinger, G, Shapiro, DB, Kolibianakis, EM, Witjes, H, Mannaerts, BM No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reprod Biomed Online. 2011 October;23(4):457–65.Google Scholar

Kolibianakis, EM, Kalogeropoulou, L, Griesinger, G et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update. 2007 September–October;13(5):445–52.Google Scholar

Xiong, Y, Bu, Z, Dai, W et al. Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2014 November 24;12:109.CrossRefGoogle ScholarPubMed

Griesinger, Georg, Finas, D, Alisch, A et al. Diedrich K and Felberbaum R. FSH time-concentration profiles before and after the administration of 0.25 mg cetrorelix in the GnRH-antagonist multiple dose protocol for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics 2004;21:279–82.Google Scholar

Al-Inany, H, Aboulghar, MA, Mansour, RT, Serour, GI Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online. 2005;10:567–70.Google Scholar

Al-Inany, H, Aboulghar, M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002;17:874–85.Google Scholar

Kolibianakis, EM, Griesinger, G. GnRH antagonists in ART In:Human Assisted Reproductive Technology: Future Trends in Laboratory and Clinical Practice. Edited by Gardner, David K, Rizk, Botros R. M. B. and Falcone, Tommaso. Cambridge University Press 2011, ISBN 978–1-107–00112-1.Google Scholar

Kolibianakis, EM, Collins, J, Tarlatzis, B et al. Among patients treated for IVF with gonadotrophins and GnRH-analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Human Reproduction Update 2006 November–December;12:6517–1.Google Scholar

Al-Inany, HG, Youssef, MA, Aboulghar, M et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011 May 11;(5):CD001750.Google Scholar

Toftager, M, Bogstad, J, Bryndorf, T et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod. 2016;31:1253–64.CrossRefGoogle ScholarPubMed

Toftager, M, Bogstad, J, Løssl, K et al. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols. Hum Reprod. 2017;32: 5566–7.Google Scholar

Tarlatzis, BC, Griesinger, G, Leader, A et al. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod Biomed Online 2012;24:4101–9.CrossRefGoogle ScholarPubMed

Griesinger, G, Verweij, PJM, Gates, D, Devroey, P, Gordon, K, Stegmann, BJ et al. Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol. PLoS ONE 2016;11(3):e0149615. doi:10.1371/journal.pone.0149615.Google Scholar

Griesinger, G., von Otte, S., Schroer, A. et al. Elective cryopreservation of all pronuclear oocytes after GnRH-agonist triggering of final oocyte maturation in OHSS risk patients: a prospective, observational proof-of-concept study. Human Reproduction 2007;22:1348–52 Russian Excerpted Edition: Human Reproduction Update 2007;2:55–9.Google Scholar

Griesinger, G, Berndt, H, Schultz, L, Depenbusch, M, Schultze-Mosgau, A. Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: A prospective, clinical cohort study. Eur J Obstet Gynecol Reprod Biol. 2010;149:190–4.Google Scholar

Al-Inany, HG, Youssef, MA, Ayeleke, RO et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016 April 29;4:CD001750.Google Scholar

Griesinger, G, Diedrich, K, Tarlatzis, B, Kolibianakis, EM GnRH-antagonists in ovarian stimulation for IVF in patients with [1] poor response to gonadotrophins, [2] polycystic ovary syndrome, and [3] risk of ovarian hyperstimulation: a meta-analysis. Reproductive Biomedicine Online 2006;13:6283–8.CrossRefGoogle Scholar

Pu, D, Wu, J, Liu, J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod. 2011;26:2742–9.CrossRefGoogle ScholarPubMed

Fauser, BC, Mannaerts, BM, Devroey, P et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update. 2009;15:3092–1.CrossRefGoogle ScholarPubMed

Griesinger, G, Boostanfar, R, Gordon, K et al. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis. Reprod Biomed Online. 2016 April 20. p ii: S1472–6483(16)30068–2. doi:10.1016/j.rbmo.2016.04.005CrossRefGoogle Scholar

Nyboe Andersen, A, Nelson, SM, Fauser, BC et al. ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril.2017;107: 3879–6.Google Scholar